Article citationsMore>>

Bartlett, N.L., Herrera, A.F., Domingo-Domenech, E., Mehta, A., Forero-Torres, A., Garcia-Sanz, R., Armand, P., Devata, S., Izquierdo, A.R., Lossos, I.S., Reeder, C., Sher, T., Chen, R., Schwarz, S.E., Alland, L., Strassz, A., Prier, K., Choe-Juliak, C. and Ansell, S.M. (2020) A Phase 1b Study of AFM13 in Combination with Pembrolizumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood, 136, 2401-2409.
https://doi.org/10.1182/blood.2019004701

has been cited by the following article:

• TITLE: Construction of Multi-Specific Antibody by Genetic Engineering and Its Progress in Tumor Therapy

  AUTHORS: Zhenqi Xu, Can Gao, Mengru Jian, Wei Du

  KEYWORDS: Genetically Engineered, Multi-Specific Antibody, Tumor Therapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.3, March 24, 2023

  ABSTRACT: Targeted treatment of cancer with monoclonal antibodies increases the benefit for patients. In order to improve the anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research field. The emergence of various techniques to produce multi-specific recombinant antibody molecules has led to the selection of target combinations in various forms. To date, only a few multi-specific constructs have entered phase III clinical trials, in contrast to classical monoclonal antibodies. Some of the format options are outlined from a technical point of view. We focus on the achievements and prospects of the underlying technologies for generating biand multispecific antibodies.